
USD
+$0.00
(+0.00%
)At Close (As of Nov 5, 2025)
$2.84B
Market Cap
106.24
P/E Ratio
0.34
EPS
$47.32
52 Week High
$22.61
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $290M |
| Total Revenue | $446M |
| Cost Of Revenue | $156M |
| Costof Goods And Services Sold | $156M |
| Operating Income | $16M |
| Selling General And Administrative | $178M |
| Research And Development | $69M |
| Operating Expenses | $294M |
| Investment Income Net | - |
| Net Interest Income | $11M |
| Interest Income | $11M |
| Interest Expense | $2K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $23M |
| Income Before Tax | $26M |
| Income Tax Expense | $1.6M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $24M |
| Comprehensive Income Net Of Tax | - |
| Ebit | $26M |
| Ebitda | $49M |
| Net Income | $24M |
| Field | Value (USD) |
|---|---|
| Total Assets | $1.3B |
| Total Current Assets | $372M |
| Cash And Cash Equivalents At Carrying Value | $239M |
| Cash And Short Term Investments | $239M |
| Inventory | $22M |
| Current Net Receivables | $47M |
| Total Non Current Assets | $928M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | $102M |
| Intangible Assets Excluding Goodwill | $102M |
| Goodwill | $746M |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | $50M |
| Other Current Assets | $15M |
| Other Non Current Assets | - |
| Total Liabilities | $124M |
| Total Current Liabilities | $79M |
| Current Accounts Payable | $8.6M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $7.5M |
| Total Non Current Liabilities | $45M |
| Capital Lease Obligations | $51M |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $51M |
| Other Current Liabilities | $61M |
| Other Non Current Liabilities | $972K |
| Total Shareholder Equity | $1.2B |
| Treasury Stock | - |
| Retained Earnings | -$444M |
| Common Stock | $78K |
| Common Stock Shares Outstanding | $78M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | $75M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $23M |
| Capital Expenditures | $11M |
| Change In Receivables | - |
| Change In Inventory | -$5.9M |
| Profit Loss | - |
| Cashflow From Investment | -$56M |
| Cashflow From Financing | $4.9M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | $24M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $290M |
| Total Revenue | $446M |
| Cost Of Revenue | $156M |
| Costof Goods And Services Sold | $156M |
| Operating Income | $16M |
| Selling General And Administrative | $178M |
| Research And Development | $69M |
| Operating Expenses | $294M |
| Investment Income Net | - |
| Net Interest Income | $11M |
| Interest Income | $11M |
| Interest Expense | $2K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $23M |
| Income Before Tax | $26M |
| Income Tax Expense | $1.6M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $24M |
| Comprehensive Income Net Of Tax | - |
| Ebit | $26M |
| Ebitda | $49M |
| Net Income | $24M |
Sector: HEALTHCARE
Industry: DIAGNOSTICS & RESEARCH
Veracyte, Inc. is a genomic diagnostics company in the United States and internationally. The company is headquartered in South San Francisco, California.